Amydis Completes Pre-IND Meeting with FDA for Development of First-in-Class Retinal Tracer for Diagnosis of ALS

Amydis announced the successful completion of a pre-IND (investigational new drug) meeting with the FDA regarding the development plans for a small-molecule tracer to detect TDP43 in the retina of amyotrophic lateral sclerosis (ALS) patients.

Amydis Completes Pre-IND Meeting with FDA for Development of First-in-Class Retinal Tracer for Diagnosis of ALS
December 07, 2021
Nacuity Pharmaceuticals Receives $16.5 Million Series B Financing to Support its Clinical Trials

Nacuity Pharmaceuticals announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round.

Nacuity Pharmaceuticals Receives $16.5 Million Series B Financing to Support its Clinical Trials
June 16, 2022
Alterations Caused by ALS Damage the Retinal Tissue, Study Reveals

Amyotrophic lateral sclerosis (ALS), which causes damage to brain neurons and the spinal cord, also damages the tissue of the retina, according to a study led by Universidad Complutense de Madrid (UCM).

Alterations Caused by ALS Damage the Retinal Tissue, Study Reveals
November 25, 2021
More